Detailed Information on Publication Record
2010
IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status
JEŽÍŠKOVÁ, Ivana, Filip RÁZGA, Monika BAJEROVÁ, Zdeněk RÁČIL, Jiří MAYER et. al.Basic information
Original name
IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status
Authors
JEŽÍŠKOVÁ, Ivana (203 Czech Republic, guarantor), Filip RÁZGA (703 Slovakia, belonging to the institution), Monika BAJEROVÁ (203 Czech Republic, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution)
Edition
Leukemia & Lymphoma, Gordon and Breach, 2010, 1042-8194
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.492
RIV identification code
RIV/00216224:14110/10:00067242
Organization unit
Faculty of Medicine
UT WoS
000285004300021
Keywords in English
acute myeloid leukemia
Tags
International impact, Reviewed
Změněno: 25/4/2014 13:05, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
In conclusion, our data demonstrate that, within the cohort of tested individuals, the IDH2 mutations are associated with AML (in contrast to healthy volunteers), suggesting a role for these mutations in disease pathogenesis. In addition, we show an association of the observed IDH2 mutations with disease status, indicating their potential for MRD monitoring. This report thus indicates that IDH2 p.R140 variants are possible markers for MRD detection. However, an extended investigation of IDH2 mutations kinetics, involving long-term followup and a larger cohort of IDH2 mutated AMLs, will be required to confirm these findings.